Technical charts for BSX stock forecast 2025 show upward momentum, with possible resistance near the $70 mark. Institutional buyers continue to accumulate positions, signaling confidence in long-term earnings growth trajectories. Boston Scientific's outlook expects $25.4 billion in revenue and $4.8 billion in earnings by 2028. This is based on an annual revenue growth rate of 11.1% and a $2.3 billion increase in earnings from the current $2.5 billion. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock With medtech innovation cycles shortening, BSX stock forecast 2025 could enjoy accelerated product adoption curves. Analysts suggest revenue outperformance if new launches achieve market share ahead of schedule.
